Introduction
Selective infection of tumour cells combined with transfer of anti-tumoural genes is an attractive strategy for cancer therapy being in focus of current research. Especially, as results from clinical trials with replicationincompetent vector systems have shown that efficient therapy requires wide or complete dispersion of the antitumoural gene within the tumour tissue. Besides, a number of different oncolytic viruses such as adenovirus, measles virus or herpes virus, g-retroviruses are being developed towards tumour therapy because of their intrinsic selectivity for mitotically active cells. [1] [2] [3] [4] [5] [6] [7] [8] [9] Moreover, g-retroviruses can integrate into the host cell genome without causing any cytopathic effect, thus offering the unique potential for persistence of the virus and a permanent anti-tumoural effect. Preclinical data on tumour mouse models demonstrated proof of principle for effective treatment of gliomas and colorectal cancer using murine leukaemia virus (MLV) equipped with an inducible suicide gene. 6, 10, 11 However, translation of this approach into clinical trials is currently hampered by serious concerns about the oncogenic potential of gretroviruses, as it was observed in the X-SCID clinical trial with a conventional non-replicative MLV vector. 12 Several layers of safety margins will therefore have to be added to replication-competent g-retroviruses before their first use in man can be considered.
Restricting virus infection at the level of cell entry is definitively among the prime issues. Besides increasing safety, targeting can make therapeutic viruses more efficient in gene delivery by diminishing the loss of virus to non-target cells also. For retroviruses, the most efficient targeting system is based on protease-activatable envelope (Env) proteins. In this system, viruses remain non-infectious until the Env protein becomes activated by cleavage through a secreted or membranebound protease that recognizes an engineered protease substrate. Tumours are known to require specific active proteases to facilitate dissemination of tumour cells and to promote angiogenesis. Among several families of proteases involved in tumourigenesis, matrix metalloproteases (MMPs) comprise the biggest number. 13 We have previously established a directed evolution-based approach that selects optimally MMP-activatable MLVs for a given tumour type from libraries of viruses displaying different protease substrate peptides. [14] [15] [16] Such selected viruses were several orders of magnitude more infectious for MMP-rich tumour cells than viruses displaying standard MMP substrates. 15 Moreover, the MMP substrates in these selected viruses have been successfully transferred to Env proteins of other viruses to restrict their tropism to tumour cells. 17, 18 MMP activation of MLV is being accomplished through fusing a blocking domain to the extracellular part of Env that renders the virus non-infectious unless the connecting linker peptide is being proteolytically cleaved so that the virus particle gets rid of the blocking domain. As blocking domain, trimerizing polypeptides like the extracellular domain of CD40 ligand (CD40L) are being used. 19 Retroviral MLV libraries containing combinatorially diversified MMP substrate peptides had been passaged on the fibrosarcoma cell line HT1080 and the glioblastoma cell line U87MG. 14, 15, 20 From the selection process on HT1080 cells two predominant linker sequences, AKGLYK and PSGLYQ, had been identified, whereas the selection on U87MG cells had resulted in the single linker peptide PAGLHV. Molecular virus clones with the selected MMP substrate peptides, designated C-AK-A, C-PS-A and C-HV-A, were shown to be superior in infectivity, selectivity and genetic stability compared to a virus containing a standard MMP substrate. 15 In the present study we investigated the in vivo biodistribution of the selected viruses and their ability to reach tumour tissue after systemic administration. We show that the viruses efficiently infect tumour tissue after intravenous injection and do also reach additionally implanted tumours. Although the wild-type (wt) virus infected extratumoural organs as well, infection of nontarget tissue was reduced by several orders of magnitude for the MMP-activatable viruses.
Results

Spreading of MMP-activatable viruses to target tumours
The ability to target HT1080-derived tumours in vivo with systemically circulating viruses was first analysed for the C-AK-A and C-PS-A viruses, which have been previously selected from a retroviral library on HT1080 tumour cells (Figure 1 ). Non-targeted wt MLV (wtMLV) without blocking domain was used as a control. A reservoir for a continuous virus delivery was established in vivo by transplanting HT1080 cells infected with the different viruses, respectively, subcutaneously into one flank of the mice (virus producing tumour). At the same time, non-infected HT1080 cells were implanted into the other flank to establish a non-infected target tumour.
Presence of virus in the target tumour was analysed 27 and 34 days after tumour cell implantation. The target tumours were removed disaggregated and the cells cultivated in the presence of azido-thymidine (AZT) to prevent any further virus spreading. To detect and quantify the virus-infected cells, immunostaining specific for the viral p30 antigen was performed (Figure 2a) . In all samples analysed, wtMLV as well as the MMPactivatable viruses were detected and thus must have spread through the mouse body (Figure 2b ). The percentage of infection was calculated as the number of infected tumour cells relative to the total number of recultivated cells. The wtMLV had infected the complete target tumour by day 27. The MMP-activatable viruses showed on average lower infection rates reaching up to 40% infected cells by day 27 (Figures 2a and b) . However, there was a relatively high variation in the number of infected cells among individual samples, which is most likely due to individual differences in settling and growth of tumour cells after implantation, as well as variations in the efficiency of tumour cell recultivation.
Next, we analysed samples from the target tumours and a number of extratumoural organs for the presence of virus by PCR. Primers for detection of exogenous MLV in murine tissue have to be designed in such a way that endogenous MLV sequences which are derived from ecotropic MLV strains do not cause false-positive signals. 21 Our virus constructs differ from ecotropic MLV strains by the env gene which is derived from the amphotropic MLV strain 4070A. Although in the wtMLV the complete env gene including the signal peptidecoding region is derived from 4070A, in the MMPactivatable viruses the Moloney murine leukaemia virus (MoMLV) signal peptide-coding region is still present. For the initial PCR analyses, a primer pair flanking the inserted blocking domain-encoding sequence had to be used to verify the genetic stability of the MMPactivatable viruses along with virus detection. Specific upstream primers binding to the signal peptide-coding region for the MMP-activatable viruses on one hand and for the wtMLV on the other hand were thus designed (see 'Materials and methods' for details) and used for PCR analysis of genomic DNA isolated from the target tumour tissues and various mouse organs. The intensities of the obtained PCR signals were correlated to those of a reference PCR performed on defined amounts of DNA isolated from C-AK-A or wtMLV-infected cells. Probe-specific PCRs were correlated to these reference PCRs to determine the amount of virus infection in tumour and organs in a semiquantitative manner. This correlation showed that the PCR on MMP-activatable viruses was more sensitive than that on the wtMLV and thus did not allow a direct comparison of the MMPactivatable and the wtMLV viruses, although signal intensities between tumour and organ PCRs can be compared for each virus type.
The PCR signals for wtMLV were comparably strong in the target tumour and in spleen and bone marrow indicating similar infection levels. Weaker signals were also seen in lung tissue. In contrast, only weak PCR signals were obtained for MMP-activatable viruses in spleen and bone marrow samples, whereas tumours gave a strong signal suggesting a higher amount of virus content (Table 1) . Notably, the PCR products from the MMP-activatable viruses were represented by a single Biodistribution of tumour-targeted retroviruses LJ Duerner et al PCR product of the expected size demonstrating their genetic stability (data not shown). We also detected signals here for heart, lung and liver, which were not detectable in the same organs in wtMLV-infected mice, most likely reflecting the much higher sensitivity of the PCR reaction for MMP-dependent viruses.
Moreover, in this experimental setting, PCR signals of the targeted and non-targeted viruses in mouse organs might not necessarily reflect direct infection events, but could be due to the metastatic potential of the tumour and thus the invasion of infected HT1080 cells into these tissues. To test the DNA samples for the presence of DNA from HT1080 cells, a PCR detecting specifically human DNA was performed. 22 Indeed, all tissues were positive for invaded HT1080 cells (Figure 3 ). It is thus likely that especially the weak PCR signals obtained in some organs with the MMP-activatable viruses were in fact derived from the invasion of infected HT1080 cells, although the PCR signals obtained with the much less- A second non-infected target tumour was implanted into the opposite flank. Figure 3 Detection of circulating virus-producing HT1080 tumour cells. Genomic DNA from different organs was extracted from a tumour-free severe combined immunodeficient (SCID) mouse (nonxenograft) or an HT1080 tumour-bearing SCID mouse (xenograft) 35 days after tumour cell application. A primer pair directed against a highly repetitive a-satellite DNA sequence of the centromere region of human chromosome 17 specifically detecting human but not mouse DNA was used for PCR. DNA extracted from the human HT1080 cell line served as positive control (PC), DNA from the murine cell line NIH-3T3 served as a negative control (NC). Arrows indicate the specific PCR product (M, muscle; K, kidney; H, heart; Br, brain; Li, liver; S, spleen; L, lung; BM, bone marrow).
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Infection of tumour tissue upon intravenous virus injection
To exclude effects on viral biodistribution by virusinfected metastasizing cells we next tested the possibility to infect tumour cells by tail vein injection. Non-infected HT1080 tumour cells were subcutaneously implanted into immunodeficient mice 1 week before virus injection. For each type of virus two mice were analysed. The MMP-activatable viruses were generated on MMPnegative 293T cells thus rendering them non-infectious for normal tissues. 15 Equal amounts of virus particles as determined by a reverse transcriptase (RT) activity assay were administered. In addition, control mice were injected with phosphate-buffered saline (PBS) only. Tumour tissues were excised and analysed for the presence of virus by immunostaining of recultivated tumour cells 2 weeks after virus injection. Cells recovered from non-infected control mice did not show any specific staining (data not shown). Tumour cells from wtMLV-infected mice were efficiently infected at the rates of 40 and 95%, respectively (Figure 4a ). Also the C-AK-A and C-PS-A viruses had infected the tumour tissue. About 1% of tumour cells were infected with the C-PS-A virus in one of two mice, while with the C-AK-A virus 7 and 10%, respectively, infected tumour cells were observed ( Figure 4a) . A nested PCR with primers flanking the blocking domain performed with genomic DNA from these tumour tissues demonstrated genomic stability of these viruses ( Figure 4b , lanes 2-5). Due to the high sensitivity of this method, also for the tumour of a C-PS-A-infected mouse, which was initially negative by immunostaining, a PCR signal was detected demonstrating virus infection also in this case (Figure 4b, lane 5) .
These data show that a single dose of systemically administered replication-competent retroviruses is sufficient to achieve infection of growing tumours.
Biodistribution of viruses after intravenous injection
Biodistribution of C-PS-A, C-AK-A and wtMLV was determined in tumour-free mice by a single intravenous injection of equal amounts of virus particles. To analyse the kinetics of virus distribution, mice were killed 1, 4 and 14 days post-infection. Genomic DNA was extracted from the organs and virus-specific sequences were amplified by PCR using primer pair Env(A)s1 and Env(A)as2 for both, wtMLV and MMP-activatable viruses. This primer pair localizes within the env gene open reading frame thus allowing a direct comparison of PCR signal intensities of the wtMLV and the MMP- Remarkably, a strong signal for wtMLV was detected in spleen already by day 1 after infection; weak signals were obtained with DNA from liver and bone marrow (Figure 5a ). Over the next 3 days not only the virus load further increased especially in bone marrow, but also the lung tissue became infected (Figure 5b ). After 2 weeks, wtMLV had infected all analysed organs except brain. At this time point, the strongest signals were obtained with DNA isolated from bone marrow, spleen and liver ( Figure 5c ). The pattern of overall biodistribution and the intensities of the PCR signals remained unchanged when mice were perfused before organ sampling (Supplementary Figure S1) . Thus, these tissues must have been infected either directly by free circulating virus or been invaded by infected blood cells. The increase in PCR signal intensities over time strongly suggests continuous wtMLV replication in the tissues. Productive replication of wtMLV was further supported by the presence of infectious virus in the blood of these mice at titre of 10 4 IU ml À1 of serum. In sharp contrast to wtMLV, specific signals for the C-PS-A and C-AK-A viruses were never detected at any time point in the analysed tissues, except from a very faint band obtained with DNA from lung of a C-AK-A-infected mouse at day 14 ( Figure 5 , data not shown).
Quantification of tumour targeting
To quantify and compare tumour targeting of wtMLV and the different MMP-activatable viruses, the virus load in tumour tissue, spleen, bone marrow and liver was determined by a highly sensitive real-time PCR approach. Besides the C-AK-A and C-PS-A viruses, we also included the C-HV-A virus in this study. This MMPactivatable virus was previously selected on the glioblastoma cell line U87MG and shown to spread through U87MG cells with the same efficiency as wtMLV. 15 To ensure optimal sensitivity and specificity of the light-cycler PCR as well as to avoid interfering signals from endogenous retroviruses, different env-specific primer pairs were carefully tested (data not shown). The optimal primer pair gave rise to a 102 bp fragment corresponding to a distinct part of the coding sequence of the variable region of the amphotropic Env protein. To further specify the PCR product, an amphotropic Env probe was used to detect virus-specific PCR products (Table 2) .
We used tumour-free mice to investigate the organ distribution and HT1080-(for wtMLV, C-AK-A and C-PS-A) or U87MG-(for C-HV-A) tumour-bearing mice, respectively, to quantify the tumour virus loads. Mice were injected intravenously with equal amounts of virus particles and genomic DNA was extracted from the different tissues 14 days after virus application. As a negative control, mice were injected with PBS. The quantification limit was determined at 0.01% infected cells (data not shown).
For all viruses, tumour tissues carried the highest virus load reaching 100% for wtMLV and between 1 and 30% for the MMP-activatable viruses (Figures 6a-d) . The grade of infection of tumour tissue with the MMPactivatable viruses was highest for C-HV-A with about 30%, followed by C-AK-A with up to 21% and C-PS-A with up to 3.4%, respectively (Figures 6b-d) . The picture was completely different for virus load in the organs of the tumour-free mice. Although wtMLV infected on an average more than 10% of the cells in liver, spleen or bone marrow (in some mice 40% virus-infected bone marrow cells were detected; Figure 6a ), the corresponding organs in mice infected with the MMP-activatable viruses contained usually less than 0.1% virus-positive cells (Figures 6b-d) . For the C-PS-A and C-HV-A viruses, Biodistribution of tumour-targeted retroviruses LJ Duerner et al infection levels within liver and spleen samples were below the limit of quantification. Thus, these organs were virtually free of virus.
Having identified the C-HV-A virus with the most favourable biodistribution profile, we compared the biodistribution of C-HV-A and wtMLV in the U87MG-based mouse tumour model. We applied equal numbers of infectious units for each virus type (that is about 10 times more C-HV-A particles) as based on titration on U87MG cells. The distribution to extratumoural organs was quantified in tumour-bearing mice at day 7 (wtMLV) and day 14 (C-HV-A). In none of the DNA samples prepared from the different organs was human DNA detectable, thus excluding the invasion of large amounts of metastasizing tumour cells (data not shown).
The C-HV-A virus showed a clear preference for tumour infection also in this experimental setting. Although about 10% of the tumour tissue was virus positive, organs were infected at very low levels not exceeding 0.03% (Figure 7) . The spreading kinetics of wtMLV was more rapid than that of C-HV-A with more than 70% infected tumour cells (Figure 7) . The load of wtMLV in bone marrow and the other extratumoural organs was generally lower in this mouse model. Thus, there was some tumour-targeting detectable for wtMLV also, which however remained far below the level of C-HV-A.
Finally, we determined tumour-targeting coefficients for each virus type by normalizing the infection rates of tumour tissue by that of bone marrow (Figure 1 ). In both tumour models, the highest targeting coefficients were obtained for the C-HV-A virus. Also the C-PS-A and C-AK-A viruses were highly selective for tumour tissue, although the C-AK-A virus was overall more infectious. The tumour-targeting capacity of wtMLV differed in both the experimental settings, most likely reflecting the different incubation periods. Yet, even at the earliest time point after infection, wtMLV tumour targeting was at least one order of magnitude lower than that of the MMP-activatable viruses.
Discussion
Targeting cells at the level of entry with viruses selected by directed evolution is a highly advantageous approach for tumour gene therapy. Previously, we demonstrated that viruses selected from libraries of MMP-activatable retroviruses, were by orders of magnitudes more efficient in spreading through MMP-rich tumour cell lines than viruses carrying a standard MMP substrate. 15 In this study we have analysed in detail the in vivo biodistribution and tumour-targeting capacity of these library-selected, MMP-activatable viruses. The viruses were able to infect established tumours upon systemic application and to reach a second distantly located tumour. Whereas non-targeted wtMLV also infected extratumoural organs, especially bone marrow, these tissues remained largely protected from infection with the MMP-activatable viruses.
Infection of bone marrow cells by wtMLV occurred as well after implantation of virus-infected tumour cells as after systemic virus application, in the latter case already 4 days post-injection. Moreover, significant titres of Biodistribution of tumour-targeted retroviruses LJ Duerner et al infectious virus were present in blood serum. Although the extent of extratumoural organ infection varied, depending on the time period allowed for virus spreading and the tumour model applied, our observations are unexpected in light of many previous reports suggesting the safe use of replication-competent MLV vectors for treatment of gliomas. These studies described an absence of extratumoural organ infection. 6, 10, 23 Comparable to our study, also in these studies a replication-competent MLV encoding the env gene of the amphotropic 4070A strain was used. The only major difference in the respective virus constructs was the presence of an additional marker (green fluorescent protein, GFP) or therapeutic (cytosine deaminase) gene. 6, 23 Although it cannot be excluded that these additional genes attenuated the viruses, it is more likely that spreading to extratumoural organs had occurred in these studies through wt-like viruses having deleted the additional genes or at least parts of them. Detection of such viruses was not possible by the PCR approach applied which used primers located within the additional genes only.
It is likely that infection of extratumoural organs is especially efficient in immunodeficient mice as used in the present study. Indeed, Hiraoka et al.
11 demonstrated the absence of MLV infection in non-tumour tissue of an immunocompetent colorectal cancer metastasis model using a highly sensitive quantitative PCR approach detecting the env gene with a similar sensitivity as in our study. Solly et al. 2 showed that low infection levels of replication-competent retroviral vectors in immunodeficient mice were reduced to undetectable levels in immunocompetent mice. However, immunodeficient mice do more closely reflect the often immunosuppressed status of end-stage cancer patients that will be the most likely patient population for first in man studies with replication-competent MLV vectors. Moreover, we observed that infection of liver and spleen occurred within the first 24 h after virus injection. At these early time points, virus infection can only be controlled by innate immunity, which is fully active in severe combined immunodeficient (SCID) mice (from: Charles River Laboratories; Informational Resources: SCID Mouse Data Sheet, 2004). Our observations raise serious safety concerns about the potential use of non-targeted MLVs in clinical cancer therapy settings, which would expose patients to the risk of MLV spreading to bone marrow and manifestation of leukaemia as seen in the recent SCID-X1 gene therapy trials. [24] [25] [26] Even if patients are in optimal immune conditions, the risk of a bone marrow infection occurring before adaptive immunity can control the virus will remain another safety issue.
Our results therefore strengthen the importance of developing more attenuated viruses with restricted tumour tropism for possible applications in patients. The MMP-activatable viruses investigated in this study are conditionally replication competent in MMP-rich tissue only. Besides tumour tissue, in the adult organism MMPs are active at sites of tissue remodelling, for example during wound healing. MMPs are highly conserved among mammalian species. The mouse repertoire of proteases is even larger than that of humans. 27 With respect to the MMP family, identity between the mouse and human members ranges between 70 and 98%. MT1-MMP and MMP2, both able to activate the applied viruses and strongly overexpressed in HT1080 and U87MG cells, are 96 and 95% identical between mouse and human, respectively. 15, 26 The active centre which is responsible for substrate recognition is even more conserved. Thus, equally efficient cleavage of the MMP substrates in the linker peptides of our MMP-activatable viruses by murine MMPs and a similar spreading pattern of MMPactivatable viruses in mice and humans can be expected.
The most favourable tumour to extratumoural tissue distribution was observed for the C-HV-A virus. This virus, which had been selected on U87MG cells from the protease substrate library C-X4-A, shows a similar replication kinetics on U87MG cell as wtMLV. 15 Its activation is mediated by MMP-2 and/or MT1-MMP, both strongly overexpressed in U87MG cells. 15, 28 In vivo, however, the C-HV-A virus was slower in spreading through U87MG tumour tissue than wtMLV. Free infectious wtMLV is present in blood serum suggesting that this virus travels from the site of injection at the tail vein to the tumour tissue by infected lymphocytes. Transport of C-HV-A in contrast may be much more inefficient. Initial infection of the tumour site can then be expected to require a longer time period or to occur at a much lower starting dose. Alternatively, an altered or inhomogenous MMP-2/MT1-MMP expression profile in the U87MG tumour tissue as compared to cultivated cells may have contributed to the reduced spreading kinetic of C-HV-A. 
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Despite its enhanced spreading capacity, at present, the risk benefit analysis appears to be negative for a clinical application of wtMLV. Even when combined with suicide gene transfer, which may not only control tumour growth but also control unwanted virus spreading, the risk of selecting escape mutants having deleted the suicide gene thus resulting in an uncontrollable virus spreading into extratumoural tissues is evident. Thus, replication-competent MLV vectors for first in man studies should be equipped with several safety layers including, for example cell entry targeting, promotor targeting and suicide gene transfer.
In this regard it is noteworthy that the MMP substrate peptides used in this study, were recently shown to mediate a restricted host range for MMP-rich cells also in the context of other viral Env proteins. 17, 18 It is remarkable, that an MMP-activatable measles virus, in contrast to its unmodified counterpart, was safe even after intracerebral injection into interferon receptor deficient mice, although retaining the full oncolytic potential. 18 Thus, the potential of tumour targeting through MMP activation may go well beyond retroviruses and become a general concept to increase the safety profile of virotherapy.
Materials and methods
Cells and viruses
Human embryonic kidney cells (HEK-293T; originally referred to as 293tsA1609neo), and HT1080 cells (human fibrosarcoma; ATCC, CCL-121) were grown according to the American Type Culture Collection in DMEM, human glioblastoma astrocytoma (U87MG; ATCC, HTB-14) was grown in EMEM. All media were supplemented with 10% fetal calf serum (GIBCO), benzylpenicillin (60 mg ml
À1
) and streptomycin (100 mg ml
). All cells were grown at 37 1C in a humidified atmosphere of 5% CO 2 .
Viruses were generated by transient transfection of HEK-293T cells with the following constructs: pM91MS, pC-AK-A, pC-PS-A and pC-HV-A, respectively (generation of plasmids described in Hartl et al.
15
). These constructs encode for the genome of MoMLV, in which the authentic env was replaced by the amphotropic 4070A env gene. pC-AK-A, pC-PS-A and pC-HV-A additionally encode the CD40L blocking domain Nterminally fused to the Env protein connected by a linker sequence of six amino acids representing the selected MMP substrate peptides. One day before transfection, 1 Â 10 7 cells were seeded into T175 cm 2 culture flasks. Plasmid DNA (28 mg) was transfected with Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions in antibiotic-free media. Supernatants of transfected cells containing the wtMLV (from pM91MS), and the MMP-activatable viruses C-AK-A (from pC-AK-A), C-PS-A (from pC-PS-A) and C-HV-A (from pC-HV-A), respectively, were harvested 48 h later and passed through a 0.45 mm filter (Millipore, Eschborn, Germany). Virus particles were concentrated by overnight centrifugation at 3000 g. Virus pellets were resuspended in PBS and stored in aliquots at À80 1C. One aliquot of each virus was subsequently quantified for RT activity using the C-type RT Activity Assay (Cavidi Tech, Uppsala, Sweden) according to the manufacturer's instructions.
To establish completely infected HT1080 cells, unconcentrated virus supernatant was transferred to HT1080 cells. The cells were cultured for several days and the percentage of infected cells was determined by immunocytochemistry for detection of the MLV p30 antigen. When all cells were stained positive, cell layers were regarded as completely infected.
Tumour application, virus injection into mice
Experimental mouse work was carried out in compliance with the regulations of the German animal protection law. CB17 SCID female mice (6-to 8-week old) were obtained from Charles River Laboratories (Wilmington, MA, USA) and maintained under pathogen-free conditions. Tumours were established by subcutaneous injections of 5 Â 10 5 HT1080 cells or 7 Â 10 6 U87MG cells, respectively, in 100 ml of PBS into the right flank of the mice. Systemic application of viruses was performed by injection of virus particles corresponding to 60 U of RT activity if not otherwise noted into the tail vein in a volume of 100 ml diluted with PBS.
Tumour and organ isolation
Mice were sacrificed and organ and tumour tissue isolated. To avoid carry over of infected tissue material from tumour to other tissues tumours were excised last. For recultivation of tumour cells from tumour tissue, about one-third of the total tumour mass was treated with collagenase for 16 h in DMEM complemented with 10 mM AZT. Cells were then further expanded in DMEM supplemented with AZT. For analysis of the viral genome, DNA was extracted from tumour and organ tissues directly after excision using the QIAamp tissue kit (Qiagen, Hieden, Germany) for bone marrow and phenol chloroform extraction for all other tissues. Tumour and organ tissues were cut into small pieces, incubated with proteinase K (500 mg ml À1 ) overnight and standard phenol-chloroform extraction was performed. DNA was precipitated by adding ethanol/ammonium acetate and resuspended in water.
PCR for virus detection
For the detection of infected cells, three different primer pairs were used ( Table 2 ). The primer pair CB6 and EASeq1(À) flanked the coding sequence for the blocking domain. It was used to detect MMP-activatable viruses and to control the genetic stability of the blocking domain coding region, giving rise to a PCR product of 655 bp. All MMP-activatable viruses contain the MoMLV-derived signal peptide in their Env, whereas that of the wtMLV was derived from the 4070A MLV strain. To detect wtMLV-infected cells EASeq1(À) was therefore used together with wtCB6, resulting in a PCR product of 157 bp. The use of different upstream primers for MMP-activatable viruses and wtMLV, respectively, resulted in a higher sensitivity of detection for the MMPactivatable viruses. Therefore, the primers Env(A)s1 and Env(A)as2 localizing within the env gene were used in parallel allowing a direct comparison of the PCR signal intensities obtained with DNA from wtMLV and MMPactivatable virus-infected tissues.
PCR was performed with genomic DNA isolated from different tissues or tumours. For the PCR with Human DNA was specifically detected with primers amplifying satellite DNA (huCr17 and huCr17a) as described in Becker et al.
22
To standardize the PCR with the primers CB6/ wtCB6/EASeq1(À), reference samples were prepared consisting of a mixture of genomic DNA (in total 500 ng) prepared from non-infected HT1080 cells and DNA isolated from cells infected with the C-AK-A (0.002-5 ng) or the wtMLV virus (1-50 ng), respectively. The signal intensities of PCR products obtained with DNA isolated from the different tissues were compared to those obtained with the reference DNA. The b-actin gene was amplified in parallel to ensure comparable quality of the isolated genomic DNA.
Quantitative PCR
To quantify the virus load in tumour tissue, spleen, liver and bone marrow real-time PCR was performed by the Microarray Facility (Tü bingen, Germany) with a Roche LightCycler 2.0. using LightCycler FastStart DNA MasterPLUS HybProbe (Roche Applied Science, Mannheim, Germany). Primers and specific probes (Table 2) were purchased from TIP MolBiol (Berlin, Germany) and labelled with LCred(640) for env gene-specific probes and LCred(705) for the reference probes to allow use in a duplex PCR. For virus detection a 102 bp fragment from the env gene was amplified using the primer pair EnvA_For and EnvA_Alt ( Table 2) . As an endogenous reference and to normalize variations in DNA extraction the human b2-microglobuline encoding gene (primer pair b2MG_se and b2MG_BK) for tumour tissue analysis and the murine b-actin encoding gene (primer pair Act_F and Act_R) for all murine samples (liver, spleen and bone marrow) were amplified in parallel. Capillary electrophoresis confirmed the specificity of all PCR products obtained. Probes for specific detection of each corresponding PCR product were b2M 3FL and b2M 5LC for b-microglobuline, Act_FL and Act_LC for b-actin, and EnvA_FL1 and EnvA_LC1 for the env gene.
A standard curve was generated by first calculating the ratio of each Cp value of env and the corresponding Cp value of the reference gene. This value was then plotted against the corresponding percentage of provirus-positive tissue. Defined dilutions of viral DNA were prepared from C-AK-A-infected HT1080 cells (for tumour tissue analysis) as well as from wtMLV-infected NIH-3T3 cells (for mouse organ analysis) and mixed with DNA from non-infected HT1080 and NIH-3T3 cells, respectively. Control DNA was prepared from 100% infected cells which had been generated by infection with an MOI of 0.05 to generate single provirus containing cell lines. Virus spreading was controlled by immunocytochemistry against the p30 protein, to confirm the presence of provirus in all cells. PCR conditions were 40 ng genomic DNA per reaction and 50 cycles (10 s 95 1C, 20 s 55 1C and 12 s 72 1C). As we applied a relative quantitation of the env target gene to an internal reference gene and used an interrun calibrator at each run for normalization with the standard curve it was possible to run the samples separately from the standard curve measurements (see Technical note no. LC_10/ update 2003 from Roche). The Cp values from the env PCR reactions were normalized to those from the reference PCR reactions. This ratio was then plotted against the percentage of provirus-positive cells, resulting in a linear regression line with a high coefficient of correlation of 0.9999 for the PCR on tumour tissue and 0.9974 for the PCR on murine tissue. The standard curve Biodistribution of tumour-targeted retroviruses LJ Duerner et al was linear over the complete range of env detection from 0.01 to 100%. To analyse the tissue samples, 100 ng genomic DNA isolated from tumour samples and 200 ng genomic DNA isolated from extratumoural tissues were analysed in triplicates under the above specified PCR conditions. Due to the use of gene-specific probes applied in the same PCR reaction, only specific PCR products were detectable. In each PCR cycle, positive and negative reference DNA (100% infected and non-infected murine or human DNA, respectively) was analysed in parallel. The mean Cp value of each triplicate was calculated and used to determine the percentage of infected tissue by setting the positive reference DNA to 100%.
Immunocytochemistry
Recultivated tumour cells were seeded into 24-well plates keeping them continuously under AZT (10 mM) treatment to prevent any further virus spreading. To confirm full activity of stocks of AZT we followed the spreading of wtMLV upon infection of HT1080 cells at low MOI in presence and absence of AZT (Supplementary Figure S2 ). After a cultivation period of utmost 5 days, when cells had reached confluence, they were fixed and stained with a goat anti-Rauscher MuLV p30 antiserum (Quality Biotech, Camden, NJ, USA) at a 1:1000 dilution, as previously described. 16 The number of red-stained cells relative to the total cell number represents the percentage of virus infection.
